Edition:
United States

Advaxis Inc (ADXS.OQ)

ADXS.OQ on NASDAQ Stock Exchange Global Select Market

6.88USD
21 Jul 2017
Change (% chg)

$-0.25 (-3.51%)
Prev Close
$7.13
Open
$7.20
Day's High
$7.26
Day's Low
$6.76
Volume
134,496
Avg. Vol
185,880
52-wk High
$16.29
52-wk Low
$5.70

Latest Key Developments (Source: Significant Developments)

Advaxis names ‍Anthony Lombardo interim CEO
Thursday, 6 Jul 2017 04:30pm EDT 

July 6 (Reuters) - Advaxis Inc :Advaxis announces change in leadership.Advaxis inc - ‍Anthony Lombardo named interim chief executive officer​.Advaxis inc - ‍Daniel J. O'Connor, chief executive officer, announced his resignation from company​.  Full Article

Advaxis says confirms is on track to initiate clinical studies of ADXS-NEO later this year
Tuesday, 13 Jun 2017 12:30pm EDT 

June 13 (Reuters) - Advaxis Inc :Company confirmed that it is on track to initiate clinical studies of ADXS-NEO later this year.Reaffirmed plans to file complete MAA for axalimogene filolisbac in Europe for treatment of metastatic cervical cancer by end of 2017​.  Full Article

Advaxis and Bristol-Myers Squibb announce clinical collaboration to evaluate ADXS-DUAL and Opdivo in metastatic cervical cancer
Tuesday, 30 May 2017 06:59am EDT 

May 30 (Reuters) - Advaxis Inc :Advaxis and Bristol-Myers Squibb announce clinical collaboration to evaluate ADXS-DUAL and opdivo (nivolumab) in metastatic cervical cancer.Bristol-Myers Squibb Co says Advaxis will sponsor study and pay third-party costs.Bristol-Myers Squibb Co - Under terms of agreement, each party will bear their own internal costs and provide its immunotherapy agents..Bristol-Myers squibb -Study expected to start by end of year.  Full Article

Advaxis Inc- European Medicines Agency issued an advanced therapy medicinal product certificate
Thursday, 23 Mar 2017 08:00am EDT 

Advaxis Inc :Advaxis Inc - European Medicines Agency issued an advanced therapy medicinal product certificate for manufacturing quality and non-clinical data.  Full Article

Advaxis says 38 pct of patients with heavily pretreated prmcc were alive 12 months following treatment with axalimogene filolisbac
Wednesday, 15 Mar 2017 07:00am EDT 

Advaxis Inc : Advaxis presents oral late-breaking data on phase 2 gog-0265 study of axalimogene filolisbac . Advaxis - final efficacy results of gog-0265 demonstrated 38% of patients with heavily pretreated prmcc were alive 12 months following treatment with axalimogene filolisbac .Advaxis inc - safety profile was consistent with previous clinical experience.  Full Article

Advaxis announces FDA acceptance of IND for groundbreaking personalized neoepitope immunotherapy, ADXS-NEO
Monday, 6 Mar 2017 06:00am EST 

Advaxis Inc : Advaxis announces FDA acceptance of IND for groundbreaking personalized neoepitope immunotherapy, ADXS-NEO .Plans to initiate a phase 1 trial evaluating ADXS-NEO in multiple tumor types later this year.  Full Article

Advaxis and Sellas announce licensing agreement for development of WT1 antigen-targeting immunotherapy
Monday, 27 Feb 2017 08:00am EST 

Advaxis Inc : Advaxis and Sellas announce licensing agreement for development of WT1 antigen-targeting immunotherapy . Advaxis Inc- Advaxis will receive future payments of up to $358 million from Sellas if certain development, regulatory, and commercial milestones are met . Advaxis Inc says advaxis will receive future payments of up to $358 million from Sellas if certain development, regulatory . Under terms of collaboration, Advaxis will conduct all pre-clinical activities required for an Ind Filin . Advaxis Inc says Sellas will be responsible for all clinical development and commercial activities .Advaxis -after regulatory approval of product Sellas to pay Advaxis single-digit to low double-digit royalties based on worldwide net sales upon commercialization.  Full Article

Advaxis files for common stock offering of up to $250 mln
Friday, 10 Feb 2017 04:58pm EST 

Advaxis Inc :Advaxis Inc files for common stock offering of up to $250 million - SEC filing.  Full Article

Amgen reports 8.9 pct passive stake in Advaxis as of Aug 1
Tuesday, 2 Aug 2016 09:06am EDT 

Amgen Inc Reports 8.9 Pct Passive Stake In Advaxis Inc As Of August 1 :Sec filing.  Full Article

Advaxis files for common stock offering
Tuesday, 2 Aug 2016 08:49am EDT 

Advaxis Inc :Files for common stock offering of up to 3.05 million shares - SEC filing.  Full Article

Advaxis CEO Daniel O'Connor resigns

Cancer immunotherapy developer Advaxis Inc said on Thursday Daniel O'Connor stepped down from his position as the company's chief executive and its board.